Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Cancer Metastatic × Ipilimumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 221 Carcinoma, Non-Small-Cell Lung 66 Carcinoma, Renal Cell 54 Neoplasm Metastasis 45 Neoplasms 38 Prostatic Neoplasms 32 Lung Neoplasms 26 Uveal Melanoma 25 Carcinoma, Hepatocellular 23 Pancreatic Neoplasms 22 Brain Neoplasms 21 Sarcoma 20 Colorectal Neoplasms 20 Breast Neoplasms 20 Squamous Cell Carcinoma of Head and Neck 16 Small Cell Lung Carcinoma 16 Skin Neoplasms 16 Kidney Neoplasms 16 Ovarian Neoplasms 14 Carcinoma, Transitional Cell 14 Urinary Bladder Neoplasms 13 Triple Negative Breast Neoplasms 12 Diabetes Mellitus, Insulin-Dependent, 12 12 Uterine Cervical Neoplasms 11 Mesothelioma 11 Stomach Neoplasms 10 Recurrence 10 Multiple Myeloma 10 Head and Neck Neoplasms 10 Glioblastoma 10

Interventions

tremelimumab 1 regramostim 1 osimertinib 1 evolocumab 1 durvalumab 1 Surgical Instruments 1 Radiotherapy 1 Radiation 1 Nivolumab 1 Needles 1 MLN 8237 1 Ipilimumab 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05144529 2025-04-17

TOP2101

Duke University

Phase 2 Active not recruiting

Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡